Tarsus Pharmaceuticals, Inc.

NasdaqGS TARS

Tarsus Pharmaceuticals, Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -12.61

Tarsus Pharmaceuticals, Inc. Price to Earnings Ratio (P/E) is -12.61 on January 14, 2025, a -113.20% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Tarsus Pharmaceuticals, Inc. 52-week high Price to Earnings Ratio (P/E) is -5.11 on August 02, 2024, which is 59.46% above the current Price to Earnings Ratio (P/E).
Tarsus Pharmaceuticals, Inc. 52-week low Price to Earnings Ratio (P/E) is -17.56 on January 07, 2025, which is -39.23% below the current Price to Earnings Ratio (P/E).
Tarsus Pharmaceuticals, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -9.20.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: TARS

Tarsus Pharmaceuticals, Inc.

CEO	Dr. Bobak R. Azamian M.D.
IPO Date	Oct. 16, 2020
Location	United States
Headquarters	15440 Laguna Canyon Road
Employees	244
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Key trends

Past 5 years